Memory CD8 T cells can be broadly divided into circulating (T) and tissue-resident memory T (T) populations. Despite well-defined migratory and transcriptional differences, the phenotypic and functional delineation of T and T cells, particularly across tissues, remains elusive. Here, we utilized an antibody screening platform and machine learning prediction pipeline (InfinityFlow) to profile >200 proteins in T and T cells in solid organs and barrier locations. High-dimensional analyses revealed unappreciated heterogeneity within T and T cell lineages across nine different organs after either local or systemic murine infection models. Additionally, we demonstrated the relative effectiveness of strategies allowing for the selective ablation of T or T populations across organs and identified CD55, KLRG1, CXCR6, and CD38 as stable markers for characterizing memory T cell function during inflammation. Together, these data and analytical framework provide an in-depth resource for memory T cell classification in both steady-state and inflammatory conditions.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.immuni.2023.06.005DOI Listing

Publication Analysis

Top Keywords

memory t cell
12
memory
5
single-cell protein
4
protein expression
4
expression profiling
4
profiling resolves
4
resolves circulating
4
circulating resident
4
resident memory
4
t cell diversity
4

Similar Publications

Article Synopsis
  • Traditional dendritic cell (DC) vaccines face challenges like poor antigen delivery, ineffective lymph node targeting, and risks from living cell transfers.
  • The new HybridDC nanovaccine uses engineered DC membranes and anchors multiple components to enhance antigen presentation and boost anti-tumor immunity.
  • HybridDC shows improved targeting of lymphoid tissues, effective treatment against glioma models, and enhances the effectiveness of immune checkpoint blockade therapies, suggesting it could revolutionize personalized cancer immunotherapy.
View Article and Find Full Text PDF

Background: The neoantigen vaccine has remarkable potential in treating advanced cancer due to its tumor specificity and ability to bypass central tolerance mechanisms. However, numerous neoantigens show poor immunogenicity, and the immune inhibitory factors of present in both tumors and tumor-draining lymph nodes impair the efficacy of cancer neoantigen vaccine. Eliminating immunosuppressive cells will improve the priming and expansion of anti-tumor immune cells induced by the vaccine.

View Article and Find Full Text PDF

Enhanced anti-tumor activity mediated by combination chimeric antigen receptor T cells targeting GD2 and GPC2 in high-risk neuroblastoma.

Cytotherapy

November 2024

Cell Therapy Center, Beijing Institute of Geriatrics, Xuanwu Hospital Capital Medical University, National Clinical Research Center for Geriatric Diseases, and Key Laboratory of Neurodegenerative Diseases, Ministry of Education, Beijing, China; Center of Neural Injury and Repair, Beijing Institute for Brain Disorders, Beijing, China. Electronic address:

Article Synopsis
  • CAR-T cells, which are engineered to target specific antigens, struggle to effectively treat solid tumors like high-risk neuroblastoma due to various challenges, including poor persistence and diverse antigen expressions.
  • A new strategy combining CAR-T cells targeting GD2 and GPC2 was developed to enhance treatment effectiveness by using a selective domain that boosts T cell activity when stimulated by a specific antibody.
  • Results showed that this combination therapy improved both the immediate and long-term anti-tumor response in laboratory studies, providing hope for better outcomes in treating this aggressive pediatric cancer.
View Article and Find Full Text PDF

Background: Tumor-associated antigen (TAA)-specific CD8(+) T cells are essential for nivolumab therapy, and irradiation has been reported to have the potential to generate and activate TAA-specific CD8(+) T cells. However, mechanistic insights of T-cell response during combinatorial immunotherapy using radiotherapy and nivolumab are still largely unknown.

Methods: Twenty patients included in this study were registered in the CIRCUIT trial (ClinicalTrials.

View Article and Find Full Text PDF

NSCLC, the most common type of lung cancer, is often diagnosed late due to minimal early symptoms. Its high risk of recurrence or metastasis post-chemotherapy makes DC-based immunotherapy a promising strategy, offering targeted cancer destruction, low side effects, memory formation, and overcoming the immune evasive ability of cancers. However, the limited response to DCs pulsed with single antigens remains a significant challenge.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!